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AbstrACt
Introduction Paediatric acquired brain injury is a 
leading cause of mortality in children in the UK. Improved 
treatment during the acute phase has led to increased 
survival rates, although with life-long morbidity in terms of 
social and emotional functioning. This is the protocol for a 
feasibility randomised controlled trial with an embedded 
qualitative study and feasibility economic evaluation. If 
feasible, a later definitive trial will test the effectiveness 
and cost-effectiveness of an online intervention to enhance 
problem solving ability versus treatment as usual.
Methods and analysis Twenty-five adolescents and their 
families identified by primary or secondary care clinicians 
at participating UK National Health Service Trusts will 
be recruited and individually randomised in a 1:1 ratio 
to receive the online intervention or treatment as usual. 
Participants will be followed up by online questionnaires 
17 weeks after randomisation to capture acceptability 
of the study and intervention and resource use data. 
Qualitative interviews will capture participants’ and 
clinicians’ experiences of the study.
Ethics and dissemination This study has been granted 
ethical approval by the South West-Exeter Research Ethics 
Committee (ref 17/SW/0083). Results will be disseminated 
via peer-reviewed publications and will inform the design 
of a larger trial.
trial registration number ISRCTN10906069
IntroduCtIon
In 2012, paediatric acquired brain injury 
(pABI) was identified as one of the leading 
causes of death in children aged 5 to 19 years1. 
In the UK, 280 children per 100 000 require 
at least 24 hours hospitalisation for trau-
matic brain injury (TBI) each year.2 When 
considering other aetiologies such as brain 
tumours, stroke and infection, there are 
even greater numbers of children surviving 
pABI.3The long-term, even life-long, effects 
on social functioning, cognition, emotions 
and behaviour mean that pABI is a leading 
cause of disability.4 5
Despite these on-going difficulties, chil-
dren with pABI do not automatically receive 
specialist education, often returning to main-
stream schools with little or no additional 
support. Furthermore, although specialist 
tertiary National Health Service (NHS) 
services do exist in the UK, there are limited 
outreach support or community services for 
ongoing and emerging difficulties.6 Families 
report struggling to access appropriate treat-
ments despite their child developing signifi-
cant and complex needs. Families also report 
significant distress and burden when caring 
for a child who has survived pABI, leading to 
an increased risk of mental health difficulties 
strengths and limitations of this study
 ► This is the first study to test an online problem-solv-
ing tool for adolescents who have survived a brain 
injury in the UK.
 ► The study explores the feasibility of recruitment 
strategies, data collection and economic evaluation 
to inform the design of a larger randomised con-
trolled trial.
 ► The effect of the online intervention on executive 
functioning is not assessed.
 ► This study is conducted online, with minimal tele-
phone support and no face-to-face contact.
 ► This feasibility study was conducted over a short 
time period thus limiting the opportunity for a long-
term follow-up. The definitive trial would include a 
follow-up period of at least 6 months.
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in parents and siblings, and a breakdown in parental 
relationships.7 Without appropriate neuropsychological 
interventions, pABI can lead to increased risk of substance 
misuse,8 mental health difficulties,9 unemployment and 
criminal behaviour in adulthood.10 Thus, the long-term 
costs of pABI to the individual, his/her family and society 
as a whole can be substantial.11
Executive function (EF) difficulties (higher-order 
cognitive processes that govern goal-directed action and 
adaptive responses to novel or complex situations) are 
common following pABI.12 These difficulties can present 
later in childhood (particularly in early adolescence), 
sometimes many years after the initial brain injury. EF diffi-
culties can have far reaching effects, including problems 
with academic achievement,13 social communication,14 
emotion and behaviour regulation15 and peer relation-
ships.16 Indeed, families caring for children with pABI 
often report that EF difficulties significantly contribute 
to their increased levels of stress.17 Effective interventions 
targeting child EF and family burden are likely to have 
significant patient benefit especially as developmental 
studies show that poor family function can also negatively 
impact on the child’s development of EF abilities.18
Despite the clear negative impact of EF difficulties 
following pABI, there is currently a paucity of research 
examining the effectiveness of interventions to improve 
function.19 In an attempt to address this gap, Wade 
and colleagues developed an online web-based prob-
lem-solving, communication and self-regulation interven-
tion for adolescents (12 to 17 years) who have survived 
a TBI, and their families (Teen Online Problem-Solving, 
TOPS).20 The development of online family prob-
lem-solving treatment for paediatric TBI was predicated 
on evidence of the reciprocity between child recovery 
and parental psychological well-being and informed 
by input from survivors of TBI and their families. Prob-
lem-solving therapy provides a systematic approach for 
coping more effectively with life’s challenges by creating 
a positive mindset and developing, implementing and 
evaluating solutions to problems.21 Online family prob-
lem-solving treatment simplifies the ABCDEs of prob-
lem-solving: defining the Aim, Brainstorming, Choosing 
the best strategy to implement, Doing it (creating a 
concrete, step-by-step plan) and Evaluating whether it 
worked. Given the focus on the family rather than the 
individual, TOPS also focuses on communication skills 
and collaborative problem-solving. For adolescents with 
executive function and problem-solving deficits following 
TBI, the steps of problem-solving also provide an exec-
utive function heuristic.22 Additionally, the programme 
teaches stress management and metacognitive strategies 
such as stopping to think before acting and self-moni-
toring that can serve to promote self-regulation. Similar 
to the face-to-face, multifamily Brain Injury Family Inter-
vention,23 online modules provide didactic information 
regarding the cognitive and behavioural consequences 
of TBI, training in problem-solving, communication 
and self-awareness/regulation and exercises to reinforce 
understanding. After completing the online modules 
on their own, families meet with a trained therapist to 
implement to the problem-solving process around an 
Aim (goal) that they have identified. Thus, the online 
problem-solving programme was grounded in the scien-
tific literature, tailored to address the unique neurobe-
havioral and family consequences of TBI and refined 
through stakeholder input.20 Problem-solving therapy has 
also been trialled as a telephone-based intervention for 
adults with mild TBI and with families of adults with more 
significant brain injury,24 suggesting its potential utility 
across age groups and modes of delivery.25
Research to date has been undertaken in the USA, 
and has focused on children and adolescents who have 
survived a TBI and their families.20 26–31 These studies 
have demonstrated improvements in EF, child behaviour, 
parental depression and family-child conflict when 
comparing TOPS with an internet-resource compar-
ison control. Families have reported finding the online 
delivery of the intervention helpful, making the interven-
tion easy to access at a time that is convenient for them. 
This is an important consideration when providing inter-
ventions for children with pABI in the UK and their fami-
lies, because brain injury services in the UK often cover 
a large geographical region (many accepting national 
referrals), and families often have multiple commitments 
when caring for these teenagers with complex needs.
Despite this emerging evidence base, it is not yet known 
whether the gains described can also be demonstrated 
in adolescents with non-traumatic brain injuries (eg, 
brain tumour, stroke), when the intervention is delivered 
remotely (ie, no initial home visit to set up the interven-
tion thus keeping delivery costs to a minimum), and if 
the intervention is cost-effective relative to treatment as 
usual (TAU).
A British version of the TOPS programme, (TOPS-UK) 
has been developed. The didactic material is presented 
with British English spelling and narration, UK-based 
information including scenarios, video clips and resource 
links. TOPS-UK has been further modified to include 
examples of those with paediatric acquired brain injury 
as well as traumatic brain injury.
The potential of TOPS-UK to have a positive effect on 
the lives of thousands of adolescents with pABI needs 
testing in a rigorous multicentre, randomised controlled 
trial (RCT) in the UK, allowing a definitive test of its 
clinical and cost-effectiveness. This feasibility study is 
designed to determine if a large RCT is feasible, with the 
ultimate aim of the research being to provide an evidence 
base for effective neuropsychological interventions to be 
recommended by the Department of Health guidelines 
(eg, NICE) for survivors of pABI.
A two-arm randomised controlled feasibility phase II 
study will be conducted.32 The aim is to assess whether 
a larger, fully powered, definitive RCT and cost-effective-
ness analysis can be successfully planned and delivered. In 
order to gain as much information as possible to inform 
a fully powered RCT, additional objectives are considered 
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in this feasibility trial, including accessing information 
related to treatment set-up, delivery costs and resource 
use (table 1).
MEthods And AnAlysIs
This is a randomised, controlled, multicentre feasibility 
study in young patients with pABI aged 12 to 18 years. 
Twenty-five participants will be randomised (minimised by 
site and type of brain injury) in a 1:1 ratio to receive TAU 
or treatment as usual plus Teen Online Problem-Solving 
(TAU + TOPS UK). Treatment allocation will not be 
blinded. The protocol (V.4.1, 30 August 2018) is regis-
tered on Current Controlled Trials ISRCTN10906069 and 
follows Standard Protocol Items: Recommendations for 
Interventional Trial guidelines.33
setting
Two settings will be utilised to examine feasibility 
outcomes associated with recruitment of adolescents 
known to have had a pABI:
1. Direct referral by clinicians of adolescents who are un-
der the outpatient care (usually neurology, neuropsy-
chology or paediatric) of five participating NHS Trusts 
in England. Screening logs will be maintained at all 
sites to record the number of patients screened and 
enrolled in the study. These sites were selected to be 
representative of the range of types of services which 
might be included in a future trial, with TAU ranging 
from no provision through to services providing multi-
disciplinary outpatient care over the long-term.
2. Recruitment from Participant Identification Centres 
(PICs) in primary or secondary care, or charitable 
organisations. Potential participants will respond di-
rectly to study promotion including leaflets/posters/
participant information sheets distributed by par-
ent-led groups, charities or support groups.
Study participation will be supported by research 
nurses at each participating NHS Trust. For participants 
directly referred to the study, nurses will make the first 
approach to the family. For those identified through 
PICs, families will be asked to contact the research nurse 
whose details are provided on the patient information 
sheet (PIS). The research nurse will support all families 
during the online consent and will be a point of contact 
for all participants during the study. The research nurse 
or other research team member will support baseline and 
follow-up measure completion. The intervention will be 
provided through online materials and video conference 
links with a coach trained in the TOPS-UK intervention. 
The coach will also receive weekly supervision from a 
qualified clinical psychologist on the research team to 
ensure treatment fidelity. The single study coach will be 
centrally based at the lead site.
Participant inclusion criteria
To be included in the study, participants will be aged 
12 to 18 years at the time of recruitment and have 
survived a pABI. Diagnosis of pABI includes: moder-
ate-to-severe TBI (Glasgow Coma Scale score <12 and/
or post-traumatic amnesia >24 hours and/or loss of 
consciousness >30 min), stroke, brain tumour, central 
nervous system infection (fungal, bacterial protozoal 
or viral origin including encephalitis, meningitis, brain 
abscess, tuberous sclerosis, acute disseminated enceph-
alomyelitis and Guillain-Barre syndrome). Participants 
must be medically stable (having reached a plateau in 
recovery following the index injury or illness). They must 
also have access to the internet, and have EF difficulties in 
the opinion of the local Principal Investigator (PI). The 
local PI is not required to undertake any EF assessment 
for the purposes of the study, but will use their clinical 
judgement, and infer from any assessments that they have 
undertaken, whether a participant is likely to be experi-
encing EF difficulties in their everyday lives. At least one 
Table 1 Study objectives
Number Study objectives
1 Are clinicians able and willing to identify 
participants (eg, has time and access to database, 
medical records or clinic lists to identify potentially 
eligible patients)?
2 Are the online screening, consent and 
randomisation process feasible?
3 How many participants at each site are initially 
eligible, approached and consented, have 
completed screening and baseline questionnaires, 
been randomised (with a recruitment target of 
at least five participants per site), completed 
treatment and completed outcome assessments?
4 Do adolescents and parents find the intervention 
and outcome measures acceptable?
5 What are parents’ and adolescents’ experiences of 
study participation?
6 Is it possible to calculate means and SD for a full 
RCT for the potential primary outcome measure?
7 What resources will be required to run a main trial?
8 Do some sites need additional support to be able 
to recruit to target in a future trial?
9 Do the trial and economic evaluation methods and 
procedures yield the information required?
10 How willing are participants to be randomised and 
complete outcome measures?
11 How well do participants adhere to the intervention 
(number of sessions completed)?
12 How many complete and analysable data sets are 
yielded, and what is the level of missing data?
13 How many participants are lost to follow-up?
14 What is the coach’s experience of supporting 
intervention delivery?
15 What are adolescent and parent experiences of 
TAU? (TAU arm)
RCT, randomised controlled trial; TAU, treatment as usual. 
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parent or guardian living with the adolescent must be 
available for the family to participate. Adolescents with 
a comorbid diagnosis of attention deficit hyperactivity 
disorder, autistic spectrum disorder or specific learning 
difficulties (eg, reading difficulties including dyslexia) 
will be eligible to be recruited.
Participant exclusion criteria
Participants will be excluded from the study for the 
following reasons: insufficient English language, capacity 
or willingness for the parent/adolescent to consent/
assent to the study; pre-injury or comorbid conditions 
such as sensory impairments and global developmental 
delay, known to impair engagement with the computer 
and treatment materials; or non-accidental brain injury.
Participant recruitment
The trial complies with the Declaration of Helsinki and 
Good Clinical Practice (GCP) guidelines. GCP compli-
ance ensures that the rights, safety and well-being of 
research participants are protected and that research 
data are reliable. At sites, the local PI, research nurse 
or other member of the research team in conjunction 
with the clinical team will identify potential eligible 
participants, usually from current outpatient clinic lists 
or review of medical records. An anonymised log of all 
participants screened with reasons for exclusion will be 
kept at site. Information sheets for both adolescents and 
their parents/guardians will be provided to potentially 
eligible families. The relevant PIS will be given in person 
to families attending an outpatient clinic, or sent by post 
with a cover letter from the recruiting clinician. All fami-
lies will be provided with contact details and informed 
that a member of the research team will contact them by 
telephone at least 24 hours after receipt of the informa-
tion to discuss the study.
During this telephone call, the parent and adolescent 
will be given the opportunity to ask questions about the 
study and to confirm whether they are interested in partic-
ipating. If interested, eligibility criteria will be checked 
with the parent to confirm suitability for the study and 
ascertain which parent will participate in the intervention 
and complete parent-rated outcomes. A summary of what 
to expect from the online screening and consent process 
will also be provided.
The process of explaining the study and determining 
eligibility of potential participants will be undertaken by 
an appropriately trained member of the research team as 
delegated by the PI, depending on local arrangements. 
All staff undertaking this process for this study must have 
completed GCP training provided by a responsible organ-
isation (eg, University, NHS Trust) and must be autho-
rised by the PI to explain the study and assess eligibility, 
on the site’s study delegation log.
online screening and consent
Informed consent and assent will be obtained via the 
study-specific website, developed and maintained by the 
UK Clinical Research Collaboration (UKCRC)-regis-
tered Peninsula Clinical Trials Unit (CTU) at Plymouth 
University.
Consent/assent
The consent process will depend on the age of the 
participants:
 ► Participants aged 16 to 18 years will provide online 
informed consent.
 ► Participants aged 12 to 15 years will provide online, 
informed assent. Those who have given assent and 
who reach the age of 16 years during the study, will be 
asked to provide online informed consent.
 ► Parents of all participants aged 12 to 15 years will 
provide online informed consent on behalf of their 
child (‘signature’ from one parent required).
 ► All participating parents will provide online informed 
consent for their own participation in the study.
Web-based consent process
The research nurse will enter on the study website brief 
details of those families who wish to participate in the study 
and who satisfy the initial inclusion/exclusion criteria. 
This will trigger an email to the adolescent, containing a 
link to the age-appropriate assent or consent form within 
the website, which the adolescent should complete.
Following completion of the adolescent assent/
consent form, a separate email will be sent to the nomi-
nated parent participant containing a link to the parental 
consent form. Parents of adolescents aged 12 to 15 years 
will be asked to consent on behalf of their adolescent in 
addition to giving consent for their own participation. 
Two reminder emails will be sent from CTU followed by 
a ‘last chance’ email, all with reminders of the study link. 
If the family has not completed the consent process after 
2 weeks, the local research team will be notified and will 
contact the family to ask if they still wish to participate in 
the study.
Face-to-face consent option
If the parent and/or adolescent has not completed 
the online consent process, CTU will inform the local 
research nurse who will telephone the family to offer the 
option of a clinic visit when the nurse can support the 
parent and/or adolescent to complete online consent/
assent.
online brIEF-2 parent-rating and allocation of study number
Following completion of the consent process, the parent 
will be prompted to complete the online Behaviour 
Rating Inventory of Executive Function, Second Edition 
(BRIEF-2)34 parent-rating questionnaire. If the parent 
does not wish to complete this immediately following 
the consent process, it will be possible to return to the 
website to complete it later. Two reminder emails will be 
sent from CTU followed by a ‘last chance’ email as above. 
Face-to face support to complete the BRIEF-2 will also be 
offered by the research nurse, as above. The parent must 
complete all elements of the BRIEF-2 before progressing 
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to the baseline measures as this is the proposed primary 
outcome measure for a definitive trial.
The website will calculate the BRIEF-2 scores. The 
website will assign a unique four-digit study number to 
each participant and participants will be identified in all 
study-related documentation by this study number. An 
email to both the adolescent and the parent will then be 
sent, inviting them to follow a web link to complete the 
baseline measures, and informing them of their study 
number.
As part of the consent process, adolescents and parents 
will be reminded via the website that they are free to with-
draw from the study at any time without giving a reason 
and without affecting further treatment.
baseline data collection (adolescent and parent self-
completion)
On receiving the link to the baseline measures page of the 
study website, the adolescent and parent will complete 
their separate baseline questionnaires. The baseline 
measures should be completed within 2 weeks; if either 
the parent or adolescent have not undertaken these after 
1 week, an email reminder to the parent (in all cases) 
and the adolescent (if adolescent measures not done) 
will be sent. In addition to the questionnaires, the parent 
will provide sociodemographic information, details of 
the adolescent’s past medical history and concurrent 
medication.
Participants will also be given the option of completing 
baseline measures with telephone support from a member 
of the research team. A £15 gift voucher will be sent to 
each family on completion of their baseline measures.
randomisation
Participants will be randomised via a web-based system 
created by the CTU in conjunction with the trial stat-
istician, using minimisation by study site and type of 
brain injury (TBI/tumour/other). Participants will be 
randomly allocated in a 1:1 ratio to receive either TAU 
or TOPS-UK + TAU. The minimisation process will retain 
a stochastic element to retain allocation concealment. If 
any participant is found to be ineligible following rando-
misation, he/she will be excluded from analyses.
This study is not blinded. Following randomisation, the 
adolescent, parent, PI and research nurse will be notified 
by email of the adolescent’s treatment allocation, and 
this information will be held on the study site file. The 
parent and adolescent will also be advised when to expect 
further contact from the research team. In addition, the 
TOPS coach will be notified of all participants allocated 
to the intervention arm (TOPS-UK + TAU).
baseline data collection (research nurse)
The research nurse or another member of the research 
team at each site will record relevant injury characteristics 
data for each adolescent (including premorbid/devel-
opmental history) in the study-specific web-based case 
report form.
recording study participation in medical notes
The research nurse will make a record of study partici-
pation in the adolescent’s hospital notes according to 
local practice, stating that consent was obtained online 
and face-to-face support was given if appropriate. The 
research nurse will file a copy of the PIS in the hospital 
notes along with printed evidence from the study website 
of the informed consent process and who was involved. 
The nurse will also send a standard letter to the partici-
pant’s general practitioner recording study participation.
IntErvEntIon
The study has two treatment arms, ‘TAU’ and ‘TAU + TOPS-
UK’. Those allocated to the TAU + TOPS UK arm will work 
through the intervention programme taking 1 to 2 weeks 
per module. One coach will be trained to deliver the 
intervention to all of the participants in the intervention 
arm. The coach will coordinate the timing of the modules 
so that all families will have completed the intervention at 
16 weeks. This will allow time for other commitments and 
holidays/breaks to be built into the schedule. The length 
of time taken to complete each module will be recorded 
to inform timing of follow-up in the main trial.
treatment as usual (control)
TAU will vary at each recruitment site because currently 
there is no evidence-based treatment for adolescents 
with pABI and their families. The type of TAU received 
will be recorded for each participant at baseline via a 
parent-rated measure of adolescent health and social care 
resource use (a modified version of the Client Service 
Receipt Inventory). There will be no opportunity for any 
TAU participants to receive the TOPS-UK intervention at 
any point during or after the study.
teen online problem-solving (intervention)
TOPS is an online intervention, which is provided by the 
Cincinnati Children’s Hospital website, via a link from the 
study website. For the purposes of this study, the US-based 
TOPS treatment content was edited to include British 
(English) spelling, narration and UK resource links, 
and modified to suit participants with pABI rather than 
traumatic brain injury only. All participants allocated to 
the TAU + TOPS-UK arm will be supported by a single 
TOPS-UK coach who will make weekly contact by video 
conference.
For those participants allocated to TAU + TOPS-UK, the 
TOPS-UK coach will contact the parent and/or adoles-
cent by telephone, introduce themselves, discuss how to 
access the treatment modules on the website and how to 
log in for subsequent video call sessions. The coach will 
email these participants a ‘start-up’ pack describing how 
to access the online materials.
Ten subsequent sessions (table 2) consisting of self-
guided didactic content regarding problem-solving skills, 
video clips modelling these skills and exercises to prac-
tise the skills, will then be completed every 7 to 10 days 
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by the family and the adolescent with pABI. The online 
modules should take 30 min to complete, with the video 
call sessions taking 60 min. The parent will work together 
with the adolescent to complete the sessions. When the 
family has reviewed the materials for each session, the 
TOPS-UK coach will conduct a video call with the adoles-
cent and parent who agreed to participate in the study. 
During this session they will review the online materials 
and practise the problem-solving skills using a problem 
identified by the family/adolescent. They will then plan 
the next session and agree a suitable time for the video 
call. Ideally, video calls will be held weekly, but this period 
can be increased as agreed through discussions between 
the coach and the family.
For all families allocated to TAU + TOPS-UK, the 
TOPS-UK coach will record details in the study database 
relating to intervention compliance for example, number 
and date of Skype sessions completed, length of each 
session, progress/engagement of adolescent and parent.
Completion of all 10 modules is expected to take each 
family 16 weeks in total. If the programme has not been 
completed after 16 weeks the intervention will be discon-
tinued at that point. Study follow-up will proceed as if the 
programme had been completed.
sample size calculation
The study will aim to screen 20 potential participants at 
each site (n=100 in total), and aim to recruit a sample 
size of 25 participants from five sites. This should provide 
sufficient data to assess the feasibility and acceptability of 
the study. Although the sample size for the full RCT will 
be estimated based on the minimum clinically important 
difference for the BRIEF score35 (5-points), the SD for 
this patient population is currently unknown. A sample 
size of 25 is considered a realistic target and would be 
sufficient to address the feasibility aims (ie, acceptability 
of questionnaires etc), as well as aiming to provide at least 
12 participants reporting quantitative baseline data to 
calculate the required SD.36
data management
The CTU data management team is responsible for data 
management. Each participant will be allocated a unique 
trial number on consenting to participate and will be 
identified in all study-related documentation by the trial 
number and initials. A record of names and addresses 
linked to participants’ trial numbers will be maintained 
by the research nurses at each site for administrative 
purposes and stored securely. This is an online study, with 
no requirement for data entry at CTU. Functions within 
the study website will remind participants to complete 
online measures, and flag up missing fields. However, 
participants will be able to progress through a question-
naire leaving data fields unfilled. The SQL Server data-
base will be designed and maintained by the CTU data 
programming teams. Access by researchers will be pass-
word protected. In order to avoid problems with mislaid 
usernames and passwords, participants will access the web 
pages through links emailed to them by CTU. Once a 
web page has been completed by the participant it will be 
locked to prevent further data entry.
Confidentiality
All data will be collected and managed in accordance with 
the Data Protection Act 1998. Each participant will be allo-
cated a unique study number and will be identified in all 
study-related documentation by their study number and 
initials. All data will be entered on a password-protected 
SQL Server database and encrypted using a stored proce-
dure. After all data cleaning has been performed and the 
database locked, anonymised data will be exported to the 
trial statistician.
data analysis plan
All randomised participants will be included in the anal-
yses according to their randomised allocation, irrespective 
of adherence to treatment in the TOPS-UK arm or receipt 
of treatment in the TAU arm. No imputation of missing 
baseline or follow-up data will be performed. The study is 
not sufficiently powered to detect a significant treatment 
effect with regard to clinical or cost-effectiveness and 
thus a formal comparison will not be undertaken. The 
reported analyses will therefore be restricted to descrip-
tive statistics on the outcome measures with appropriate 
point estimates (mean, median, percentage, etc), SD and 
95% CIs for between group differences. For the question-
naire outcomes, approaches to missing individual items 
will be in accordance with the guidelines for missing item 
procedures for each questionnaire. Where no guidelines 
for individual missing items are available, the mean of 
the completed items will be used to replace missing items 
if 10% or fewer are missing. Statistical analyses will be 
Table 2 TOPS-UK sessions (complete 10 in total)
Core sessions (complete all 
five)
Getting started and staying 
positive
Steps of problem-solving
Getting organised
Staying in control
Taking care of you
Tailored sessions (choose 
four)
Dealing with fatigue
Managing fear and worry
Controlling your anger and 
improving communication
Listening, talking and reading 
non-verbal cues
Social behaviour and joining 
a group
Working with the school
Core final session Bringing it all together
TOPS-UK, Teen Online Problem-Solving, British version. 
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performed following final data cleaning and locking of 
the dataset. No interim analyses are planned. All analyses 
will be performed using Stata V.14 and will be performed 
by a statistician using a data set with treatment allocation 
masked.
Assessment of trial feasibility
The primary feasibility outcomes of this study include: (i) 
number of participants at each stage of the study, at each 
site, with stages including: identified as potentially eligible, 
approached, consented to study, completed screening 
and baseline, randomised (with at least five participants 
being recruited at each site), completed treatment and 
completed outcome assessments; (ii) any difficulties 
experienced at sites that may affect their ability to recruit 
in future will be identified and reviewed; (iii) evaluation 
of appropriateness of the trial and economic evaluation 
methods and procedures; (iv) assessment of participants’ 
willingness to be randomised to treatment allocation; (v) 
adherence to treatment assessed as number of sessions 
completed, a session will be recorded as complete if the 
participant has been through every page, reached the 
end and completed the coach web-linked session related 
to that material (with a target of participants completing 
at least five sessions) and (vi) attrition (with a target 
of at least 80% of participants completing follow-up 
assessments).
We will report the proportion of screened families who 
are found to be eligible, the proportion of eligible families 
who are recruited and randomised to their allocation and 
the proportion of randomised participants who provide 
outcome data at follow-up, with 95% CIs. Our sample size 
of 25 participants will allow us to estimate loss to follow-up 
(anticipated to be 20%) with a 95% CI of +/-13 percentage 
points. The further outcome is evaluation of the SD of the 
BRIEF-2 (parent) score for this patient population. This 
is the proposed primary outcome for the main trial and 
required for calculation of the sample size.36
Measurement of outcomes
This feasibility study aims to evaluate all aspects of the 
proposed fully powered RCT and cost-effectiveness 
analysis including recruitment and retention numbers, 
and completion of outcome measures proposed for the 
main trial. Outcomes will be assessed by questionnaires 
and interviews. Table 3 provides a summary of outcome 
measures for this feasibility trial.
Table 3 Summary of outcome measures
Outcome group Outcome measure Objective Evaluation time point(s)
  Primary outcome (main trial) Parent BRIEF-2 6 Baseline, 17 weeks post-
randomisation
Secondary outcomes
(main trial)
Adolescent: RCADS, SDQ, 
CBQ, BRIEF-2, CHU-9D
Adult: RCADS, SDQ, EQ-5D-
5L*, PHQ-9*, GAD-7*, CBQ, 
CSRI
1,10,11 Baseline, 17 weeks post-
randomisation
Measures of adherence 
(intervention group)
Participation in weekly Skype 
sessions.
Record of login to intervention 
website (frequency, duration, 
progression)
3,11 Data recorded by coach.
Data captured automatically 
by database throughout 
16 week intervention period.
Intervention feasibility and 
acceptability (intervention 
group)
Qualitative interviews with 
families
Intervention acceptability 
questionnaires (adolescent 
and parent)
Qualitative interview with 
coach
1–4, 6, 9 End of trial
17 weeks post-randomisation
End of trial
Experience of TAU (TAU arm) Qualitative interviews with 
families
15 End of trial
Study acceptability (both 
groups)
Study participation 
questionnaires (adolescent 
and parent)
Qualitative interviews 
(adolescent and parent)
5 End of trial
*Measures relating to parental outcome.
BRIEF-2, Behaviour Rating Inventory of Executive Function, Second Edition; CBQ, Conflict Behaviour Questionnaire; CHU-9D, Child Health 
Utility 9D; CSRI, Client Service Receipt Inventory; EQ-5D-5L*, EuroQol 5 Dimensions 5 Levels Questionnaire; GAD-7*, Generalised Anxiety 
Disorder 7-item; PHQ-9*, Patient Health Questionnaire 9; RCADS, Revised Child Anxiety and Depression Scale; SDQ, Strengths and 
Difficulties Questionnaire; TAU, treatment as usual.
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outcome measures
These are detailed in table 4. The proposed primary 
outcome for the main trial is the BRIEF-2,34 a parent 
and self-report measure of everyday executive func-
tion skills. Secondary outcomes will include parent 
reports of their child’s health and behaviour, using the 
Revised Child Anxiety and Depression Scale37 (RCADS) 
and Strengths and Difficulties Questionnaire38 (SDQ) 
to evaluate the adolescents’ social, emotional and 
behavioural functioning.
A mixed methods approach (questionnaires and 
interviews) will be used to address outcomes relating to 
adolescent and parent acceptability of the intervention 
and outcome measures, coach’s experience of supporting 
intervention delivery, parents’ and adolescents’ experi-
ences of study participation, assessment of participants’ 
Table 4 Trial schedule
Study procedure Screening Baseline
Follow-up
17 weeks
Consent/assent 
(adolescent+/-parents)
X
16
 w
ee
k 
in
te
rv
en
tio
n 
p
er
io
d
Consent (parents) X
Characteristics of ABI 
(CRF)
X
Current medication 
(adolescent)
X X
BRIEF parent-rating X X
Parents
  Demographics, past 
medical history
X
  SDQ parent-rated X X
  PHQ-9 X X
  GAD-7 X X
  CBQ X X
  EQ-5D-5L X X
  CSRI X X
  RCADS parent version X X
Adolescents
  Consent/assent 
(participants+/-
parents)
X
  BRIEF-2 X X
  RCADS X X
  SDQ X X
  CHU-9D X X
  CBQ X X
Both parent and 
adolescent
  Treatment adherence X
  Treatment 
acceptability rating
X
  Study participation 
feedback
X
  Qualitative telephone 
interviews (all)
X
ABI, acquired brain injury; CBQ, Conflict Behaviour Questionnaire; CHU-9D, Child Health Utility 9D; CRF, case report form; CSRI, Client 
Service Receipt Inventory; BRIEF-2, Behaviour Rating Inventory of Executive Function, Second Edition; EQ-5D-5L, EuroQol 5 Dimensions 5 
Levels Questionnaire; GAD7, Generalised Anxiety Disorder 7-item; PHQ-9, Patient Health Questionnaire 9; RCADS, Revised Child Anxiety and 
Depression Scale; SDQ, Strengths and Difficulties Questionnaire. 
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willingness to be randomised to treatment and complete 
outcome measures, evaluation of appropriateness of the 
trial and economic evaluation methods and procedures 
and adolescent and parent experiences of TAU (TAU 
arm).
Parental reports of their own and family quality of 
life, health, emotional functioning and family interac-
tions will be evaluated using the EuroQol 5 Dimensions 
5 Levels questionnaire39 (EQ5D-5L), the Patient Health 
Questionnaire40 (PHQ-9), the Generalised Anxiety 
Disorder41 (GAD-7) questionnaire and the Conflict 
Behaviour Questionnaire42 (CBQ).
Use of health and social care resources will be assessed 
through parental report on the Modified Client Service 
Receipt Inventory43 (CSRI). Adolescents involved in the 
study will also complete questionnaires relating to their 
executive function skills (BRIEF-234 adolescent version), 
quality of life (Child health-related quality of life44; 
CHU-9D), emotional functioning (RCADS),37 social, 
emotional and behaviour functioning (SDQ)38 and their 
family interactions (CBQ).42
The EQ-5D-5L and CHU-9D also provide data on 
quality-adjusted life-years (QALYs) which can be used in 
cost-effectiveness analyses.
Follow-up questionnaires
Adolescents and their parents in both treatment arms will 
be sent an email asking them to complete their online 
follow-up outcome measures at 17 weeks post-rando-
misation. In the event of non-completion, at least two 
reminders will be sent by email, followed by a reminder 
telephone call from the site research team if required. 
As with the baseline measures, participants will be given 
the option (at consent/assent) to complete the online 
follow-up measures with telephone support from a 
member of the research team. If participants do not 
complete the follow-up measures within 4 weeks they 
will receive a ‘last chance’ email with a reminder of the 
study link. A £15 gift voucher will be sent to each family 
following completion of the follow-up questionnaires.
It is acknowledged that a definitive trial would require 
longer follow-up than this feasibility study will provide, 
but the feasibility trial will inform the acceptability of 
outcome measures and the experience of participating in 
the trial. The power calculation for a definitive trial with 
longer follow-up will account for a higher level of attri-
tion than this feasibility trial.
QuAlItAtIvE IntErvIEws
A single qualitative researcher will conduct semi-struc-
tured qualitative process evaluation interviews by tele-
phone or video call with all participants (including those 
who have not completed follow-up questionnaires but who 
have not formally withdrawn from the study), research 
nurses and the study coach. PIS relating to the qualitative 
interviews will be emailed in advance and consent will be 
sought at the beginning of the interview by the qualitative 
researcher. Adolescent and parent participants will be 
offered the option of being interviewed together or sepa-
rately. Interviews will be conducted with the help of an 
agreed topic guide (see online supplementary appendix) 
and are expected to last between 20 to 60 min. Interviews 
will be audio-recorded and transcribed verbatim. The 
transcribed interview data will be fully anonymised and 
any demographic data about participants will be stored 
separately. Qualitative interview data will be managed 
using a computer software package such as Nvivo 11 and 
thematically analysed.45 The analysis and results will be 
checked/validated by a second qualitative researcher. 
The following interviews will be conducted:
1. All participants (both groups). These interviews will al-
low participants to describe their whole experience of 
participating in the study including their willingness to 
be randomised and their experiences and acceptabil-
ity of outcome measures, what worked well and what 
less well. This will cover aspects such as clarity of PIS, 
acceptability and ease of completing the online con-
sent process, ease of completing online questionnaires 
and the parental support required the adolescent to 
participate and remain engaged. The interviews will 
explore adolescent and parent experiences of TAU or 
TAU + TOPS-UK, including parent’s perceptions of 
the impact of TAU/TAU + TOPS-UK on their ability to 
support the adolescent, adolescent’s and parent’s per-
ceptions of the impact of TAU/TAU + TOPS-UK on 
adolescent’s ability to stay positive, solve problems, be 
organised, control their emotions and look after them-
selves (self-care), and participants’ views on potential 
improvements to TAU/TAU + TOPS-UK. In addition, 
participants in the TAU + TOPS-UK will be asked about 
their experience of working with the coach via video 
calls. This information will be helpful when planning 
the full RCT and implementation studies. After com-
pletion of the interview, each family will be sent a £15 
gift voucher as a token of appreciation.
2. Interview with TOPS-UK coach. A single interview 
will explore the coach’s experiences of supporting the 
TOPS-UK intervention. The interview will be held by 
telephone, or face-to-face, once every participant allo-
cated to the intervention arm has completed the pro-
gramme.
3. Interviews with research nurses. All research nurses in-
volved with the study at the five participating sites will 
be invited to participate in a single interview to explore 
their experiences of supporting families through the 
consent process and any support required to complete 
baseline or follow-up measures. Feedback on methods 
of contact with families, number of contact attempts 
made, how much support was required from adoles-
cents and/or parents, barriers to recruitment and sug-
gestions for future studies will also be sought.
Participants who withdraw from the study, participants 
who register their interest but do not complete the study 
consent forms and participants who discontinue the 
intervention and who do not complete the follow-up 
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questionnaires (ie, non-adherent but not explicitly with-
drawn), will be invited to complete an anonymous online 
feedback survey. The survey will invite participants to 
comment on any aspects of the study that they found diffi-
cult, any aspects of the study that they liked and sugges-
tions on how the study can be improved.
EConoMIC EvAluAtIon
This feasibility study will be used to develop a framework 
for a subsequent, policy-relevant, cost-effectiveness anal-
ysis to be undertaken alongside a future RCT. Economic 
evaluation methods will be developed and assessed 
regarding the collection of resource use, cost and outcome 
data. Data on resource use associated with the set-up and 
delivery of the TOPS treatment will be collected at the 
participant and coach level for example, coach contact 
and non-contact time per participant, equipment and 
consumable costs, training and supervision requirements 
for the TOPS-UK coach. Data regarding service use will 
be collected from all participants’ parents using a version 
of the CSRI specifically modified for this population. 
This includes use of mental health, community rehabili-
tation and neuropsychology and educational psychology 
services and has been previously trailed in this population 
(Wilson et al, in preparation). In addition to informing 
the development of the economic evaluation methods, 
this will provide a profile of the resources and services 
that constitute TAU. The study will also consider the 
most appropriate manner in which to capture data on 
health-related quality of life for use in the estimation of 
the cost per QALY of the TOPS-UK treatment. The feasi-
bility of participants self-completing the CHU-9D and 
parents completing the EQ-5D-5L, will be assessed.
In addition to this primary economic outcome, the 
appropriateness of considering the cost-per unit change 
on other relevant indicators of health status collected in 
the baseline and follow-up phases will be explored.
sAFEty rEPortIng
The risks associated with participating in this study are 
considered minimal. There is a slight chance for those 
in the intervention group that raising awareness of inju-
ry-related cognitive or behavioural problems through 
communication and problem-solving might increase 
family burden and possibly contribute to conflict between 
family members. However, the purpose of the interven-
tion is ultimately to equip families with skills to handle 
these difficulties by learning how to change the way 
they solve problems and talk with one another, and the 
TOPS-UK coach supporting the online intervention will 
be trained to handle any emerging problems. Should any 
issues arise, the coach will have access to a qualified clin-
ical psychologist to provide further support and advice. 
There is therefore no requirement to report non-serious 
adverse events in this study, although serious adverse 
events (SAEs) will be monitored.
SAEs may be reported by clinicians or researchers at site, 
the TOPS-UK coach, by participants themselves or by any 
other informant. Adverse event data will be monitored by 
the Trial Steering Committee (TSC) to ensure safety. The 
TSC includes an independent statistician, psychologist, 
paediatrician and patient and public representative and 
will meet on approximately four occasions. All suspected 
SAEs will be reported within 24 hours of discovery to the 
CTU who will notify the Chief Investigator. All SAEs will 
be followed up until resolution.
PArtICIPAnt And PublIC InvolvEMEnt
A PPI group including patients and the CI was convened 
at an early stage of grant development and trial design 
and continued to meet during study set-up. The group 
gave feedback on the patient-facing materials including 
age-appropriate PIS, informed consent forms and quali-
tative interview topic guide content. A lay-representative 
who is Director of Services and Innovation at the national 
Child Brain Injury Trust (CBIT) is a co-applicant to the 
grant, and a member of both the Trial Management 
Group (TMG) and TSC. During the recruitment period, 
this lay-representative has been liaising with local CBIT 
representatives and PICs to identify potentially eligible 
families. A study twitter account will post trial updates to 
promote public engagement with the study. The twitter 
site currently follows and is followed by national brain 
injury charities disseminating trial updates to a wide 
audience.
Another PPI representative (parent of a child with 
pABI) is a member of the TMG, regularly attending 
meetings and freely contributing to the discussions. Both 
members provide advice and suggest solutions to prob-
lems encountered during the trial, with particular exper-
tise in barriers to recruitment and communication issues 
within families with a teenager with pABI. This expertise 
has been cascaded to site staff through a research nurse 
forum.
The contribution of PPI members within the TMG 
and TSC will be valuable during analysis, interpreta-
tion and dissemination of the study results. Specifically, 
PPI members will be asked to contribute to data inter-
pretation, assess whether the feasibility study has met its 
objectives and support different approaches to dissemi-
nation of the study. They will also be asked to comment 
on potential changes for the main trial. The Director of 
Services and Innovation at CBIT will also support wider 
PPI in the development of the main trial.
study MAnAgEMEnt And ovErsIght
The study sponsor organisation is the Royal Devon and 
Exeter NHS Foundation Trust, Barrack Road, Exeter 
EX2 5DW. Day-to-day trial management is administered 
through the UKCRC-registered Peninsula Clinical Trials 
Unit at Plymouth University. A Trial Management Group 
including the Chief Investigator, CTU trial managers, 
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trial statistician and other personnel relevant to the study 
(eg, clinicians, CTU data manager, patient and Sponsor 
representatives) will meet regularly (usually monthly) 
throughout the duration of the trial to oversee practical 
management of the trial.
A TSC, chaired by an independent member, will oversee 
the conduct and safety of the trial, ensuring that mile-
stones are achieved and general scientific probity is main-
tained. A Data Monitoring Committee was not required 
for this feasibility study.
Ethics and dissemination
The study will be undertaken at acute NHS Trusts, subject 
to appropriate Research Ethics Committee (REC) and 
Health Research Authority approvals. The trial will be 
conducted in accordance with the protocol, the princi-
ples of the Declaration of Helsinki and International 
Conference on Harmonisation (ICH) Good Clinical 
Practice (GCP). Any amendments of the protocol will 
be submitted to the REC for approval. On request the 
Chief/Principal Investigator should make available rele-
vant trial-related documents for monitoring and audit by 
the Sponsor or the relevant Research Ethics Committee.
The study team will prepare a plain English summary 
of the study results which will be sent to the study partic-
ipants as soon as possible after the end of the study. The 
final results of the study will be disseminated via presenta-
tions at appropriate scientific meetings and conferences 
and publication in appropriate peer-reviewed journals. 
The data from this study will be used to inform the design 
and accompanying grant application for a fully powered 
RCT should the study be considered feasible.
dIsCussIon
In our opinion, TOPS-UK has genuine potential to have 
a profound and positive effect on the lives of thousands 
of adolescents with brain injury. The intervention itself 
already exists and has demonstrated efficacy in the USA, 
including gains in executive function (planning, prob-
lem-solving), reductions in behaviour and mood difficul-
ties and reductions in family burden and stress. TOPS-UK 
urgently requires testing in a rigorous multicentre 
randomised trial in the UK, allowing a definitive test of its 
clinical and cost-effectiveness.
The importance of the current study is to determine if a 
large RCT is feasible (eg, recruitment, access to resource 
use data, appropriate outcome measures etc). In addition, 
although the study is not powered to detect effectiveness, 
individual patients participating in the study might gain 
direct benefit from the treatment (TAU + TOPS) in terms 
of increased executive function skills, reduced behaviour 
and mood difficulties, and improved quality of life. The 
feasibility study might also have some implications on 
clinical and public health practice by raising awareness of 
pABI, the need for effective treatment, and the variability 
of TAU (via the dissemination workshop and reports), 
and improve the measurements of quality of life and 
health status in adolescents with pABI (via conferences). 
If the current study demonstrates feasibility, outcomes 
will be used to inform the development of a fully powered 
phase III RCT to examine effectiveness and cost-effective-
ness of TOPS-UK.
If the phase III RCT is successful, then the clinical and 
public health practice developments are potentially far 
reaching. For example, in addition to the direct benefits to 
the adolescent and his or her family, TOPS-UK might also 
prevent considerable NHS costs in the future by reducing 
healthcare service use. Furthermore, given the increased 
risks of criminal behaviour and poor educational and 
vocational outcomes following pABI, often associated 
with poor executive functioning, TOPS-UK might have 
wider social benefits for these individuals, and society 
as a whole. In terms of potential impact on local poli-
cy-making and improvement in service delivery, TOPS-UK 
is potentially very cheap to deliver because it is web-based 
and involves regular but brief professional support that is 
delivered remotely (via video calls). Furthermore, given 
its web-based delivery that can be accessed at a time that is 
convenient for the adolescent and their family, TOPS-UK 
is less disruptive than clinic appointments, which are 
often delivered during school-hours. This is an important 
consideration for an individual with pABI because, typi-
cally, the adolescents have already missed a significant 
amount of school and struggle academically. By enabling 
free use of the materials to the NHS, clinical services 
might routinely provide TOPS-UK to adolescents with 
pABI and their families, meeting the needs of multiple 
families simultaneously. TOPS-UK might also provide a 
first-line of treatment for families experiencing distress 
and, therefore form part of a ‘stepped-care’ model of 
service delivery such that, families who continue to expe-
rience significant difficulties, or who are at high risk, can 
be referred to specialist services in a timely manner. The 
ultimate aim of the research programme is to provide an 
evidence-base for effective neuropsychological interven-
tions to be recommended by the Department of Health 
guidelines (eg, NICE) for survivors of pABI.
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